Grove Biopharma

Grove Biopharma is a private, pre-clinical-stage biotech developing a breakthrough platform for intracellular drug delivery. Its core technology, Bionic Biologics™, uses precision polymerization to create synthetic, cell-permeable polymers that can engage challenging intracellular protein-protein interaction targets. The company has demonstrated proof-of-concept across several high-value targets, including MYC and KRAS, and is backed by a $30 million Series A financing to advance its pipeline in oncology, neurodegenerative diseases, and rare disorders.

Bionic Biologics™: A target-agnostic platform using precision polymerization to create synthetic, cell-permeable, protein-like polymers from peptide inputs. These modular molecules are designed to disrupt or degrade intracellular protein-protein interactions (PPIs) and can be configured as monofunctional disruptors or bispecific degraders.

Grove competes in the targeted protein degradation and intracellular PPI space against modalities like PROTACs, molecular glues, cyclic peptides, and cell-penetrating antibodies. Its differentiation lies in its synthetic polymer-based, protein-scale architecture designed for large PPI interfaces.